Demographic and disease characteristics at baseline
| eoJIA n=60 | ERA n=38 | PsA n=29 | Overall n=127 | |
|---|---|---|---|---|
| Age at baseline, years | 8.6 (4.6) | 14.5 (1.6) | 14.5 (2.0) | 11.7 (4.5) |
| 2–4 years n (%) | 15 (25.0) | – | – | 15 (11.8) |
| 5–11 years n (%) | 23 (38.3) | – | – | 23 (18.1) |
| 12–17 years n (%) | 22 (36.7) | 38 (100.0) | 29 (100.0) | 89 (70.1) |
| Female, n (%) | 41 (68.3) | 8 (21.1) | 23 (79.3) | 72 (56.7) |
| Weight, kg | 34.8 (18.9) | 54.4 (8.8) | 60.0 (14.2) | 46.4 (19.0) |
| BMI, kg/m2 | 17.9 (3.6) | 19.5 (2.4) | 22.7 (4.5) | 19.5 (4.0) |
| Age at onset | 6.1 (4.5) | 12.5 (2.1) | 12.6 (2.7) | 9.5 (4.8) |
| Disease duration, months | 31.6 (31.7) | 23.0 (19.8) | 21.8 (20.2) | 26.8 (26.4) |
| HLA-B27 presence, n (%) | 9 (15.0) | 26 (68.4) | 3 (10.3) | 38 (29.9) |
| Disease characteristics | ||||
| PGA of disease activity VAS | 5.0 (1.8) | 5.4 (1.9) | 4.7 (1.4) | 5.0 (1.8) |
| Parent global assessment of child's overall well-being VAS | 4.8 (2.4) | 5.4 (2.3) | 4.6 (2.2) | 5.0 (2.3) |
| No. of active joints | 7.6 (5.1) | 5.2 (3.6) | 7.0 (4.3) | 6.7 (4.6) |
| No. of joints with LOM | 6.3 (4.4) | 4.8 (4.0) | 5.6 (4.1) | 5.7 (4.2) |
| No. of painful joints | 5.5 (4.1) | 6.7 (4.9) | 7.8 (7.0) | 6.4 (5.2) |
| No. of swollen joints | 6.5 (4.8) | 3.8 (2.8) | 5.6 (3.7) | 5.5 (4.2) |
| CRP, mg/l* | 6.3 (10.6) | 15.3 (21.5) | 3.2 (4.7) | 8.2 (14.7) |
| CHAQ score | 0.9 (0.7) | 0.7 (0.5) | 0.7 (0.6) | 0.8 (0.6) |
| Parent global assessment of child's pain VAS | 4.8 (2.6) | 5.8 (2.5) | 4.6 (2.3) | 5.1 (2.5) |
| Morning stiffness, minutes | 72.8 (97.2) | 89.3 (128.9) | 54.3 (54.2) | 73.5 (100.6) |
| JIA category-specific characteristics | ||||
| Tender entheseal score | – | 5.9 (9.4) | – | – |
| Overall back pain VAS, mm | – | 25.9 (28.0) | – | – |
| Nocturnal back pain VAS, mm | – | 16.4 (27.8) | – | – |
| Modified Schober's test, cm | – | 15.0 (1.9) | – | – |
| Psoriasis BSA, % | – | – | 10.4 (13.4) | – |
| PGA of psoriasis | – | – | 1.8 (1.4) | |
| Concomitant therapy, no. of subjects (%)† | ||||
| Any DMARD | 54 (90.0) | 32 (84.2) | 23 (79.3) | 109 (85.8) |
| Methotrexate | 49 (81.7) | 18 (47.4) | 19 (65.5) | 86 (67.7) |
| Sulfasalazine | 3 (5.0) | 12 (31.6) | 4 (13.8) | 19 (15.0) |
| Chloroquine | 1 (1.7) | 0 | 0 | 1 (0.8) |
| Hydroxychloroquine | 1 (1.7) | 2 (5.3) | 0 | 3 (2.4) |
| Oral corticosteroid | 7 (11.7) | 8 (21.1) | 1 (3.5) | 16 (12.6) |
| Oral NSAID | 32 (53.3) | 26 (68.4) | 16 (55.2) | 74 (58.3) |
All values are mean (SD), unless otherwise specified.
*Normal ranges for CRP values were as follows: 0–3 years, female <7.9 mg/l, male <11.2 mg/l; 4–10 years, female <10.0 mg/l, male <7.0 mg/l; 11–14 years, female <8.1 mg/l, male <7.6 mg/l; 15–17 years, female <7.9 mg/l, male <7.9 mg/l; 18–120 years, female <5.0 mg/l, male <5.0 mg/l.
†Number of patients within concomitant therapy groups differ from baseline only for oral NSAIDs where two subjects in each treatment group added an oral NSAID post baseline.
BSA, body surface area; CHAQ, Childhood Health Assessment Questionnaire; CRP, C-Reactive Protein; DMARD, disease-modifying anti-rheumatic drug; eoJIA, extended oligoarticular Juvenile idiopathic arthritis; ERA, enthesitis-related arthritis; LOM, limitation of motion; NSAID, Non-steroidal anti-inflammatory drug; PGA, physician global assessment; VAS, Visual Analogue Scale.